Triple-Gene Announces Presentation at Upcoming Biotech Showcase Investor Conference
Triple-Gene Announces Presentation at Upcoming Biotech Showcase Investor Conference
- Company to Discuss First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure -
-公司將討論治療心力衰竭的第一個多基因研究治療候選藥物-
GERMANTOWN, Md.,Jan. 9, 2020/PRNewswire/ --Triple-Gene LLC, a clinical stage cardiovascular gene therapy company, today announced thatThomas D. Reed, PhD, Co-Founder, will present at the Biotech Showcase onJanuary 15th, 2020 at11:30AM PTat the Hilton San Francisco Union Square.
亞洲網馬里蘭州日耳曼敦2020年1月9日電臨牀階段心血管基因治療公司Triple-Gene LLC今天宣佈，聯合創始人托馬斯·D·裏德博士(Thomas D.Reed)將於2020年1月15日上午11：30在舊金山聯合廣場希爾頓酒店(Hilton San Francisco Union Square)舉行的生物技術展示會上亮相。
Triple-Gene's investigational therapy INXN-4001 for the treatment of heart failure comprises a multigenic plasmid designed to constitutively express human S100A1, SDF-1α, and VEGF165 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling, respectively. The non-viral plasmid therapy targeted at addressing the underlying molecular mechanisms of pathological myocardial remodeling is delivered via Retrograde Coronary Sinus Infusion (RCSI), which allows for cardiac-specific delivery to the ventricle.
用於治療心力衰竭的三基因研究療法INXN-4001包含一種多基因質粒快遞人S100A1、SDF-1α和VEGF165基因產物分別影響祖細胞募集、血管生成和鈣處理。非病毒質粒治療旨在解決病理性心肌重構的潛在分子機制，通過逆行冠狀靜脈竇輸注(RCSI)傳遞，這允許心臟特異性傳遞到心室。
The Company recently completed enrollment in its Phase I trial (clinical trial identifier:NCT03409627) of INXN-4001. Dr. Reed's presentation will highlight the advantages of Triple-Gene's approach and preliminary data from the Phase I study.
About Triple-Gene
關於三重基因
Triple-Gene LLC is a clinical stage gene therapy company focused on advancing targeted, controllable, and multigenic gene and cell therapies for the treatment of complex cardiovascular diseases. The Company's lead product is a non-viral investigational gene therapy candidate that drives expression of three candidate effector genes involved in heart failure. Triple-Gene is a majority owned subsidiary of Intrexon Corporation*(NASDAQ: XON) founded byAmit Patel, MD, MS, andThomas D. Reed, PhD, Founder and Chief Science Officer of Intrexon. Learn more about Triple-Gene atwww.3gtx.com.
*Intrexon Corporationannounced onJanuary 2, 2020that it will refocus the company on healthcare, will change its name to Precigen, Inc., and has appointedHelen Sabzevari, PhD, as President and CEO. The parent company will continue to hold, among its several health assets, majority interest in Triple-Gene's discovery and clinical stage technology and programs.
*Intrexon Corporation於2020年1月2日宣佈，它將重新將公司的重點放在醫療保健上，並將更名為Precigen，Inc.，並任命海倫·薩布澤瓦里博士為總裁兼首席執行官。在其幾項保健資產中，母公司將繼續持有Triple-Gene的發現和臨牀階段技術和項目的多數股權。
Safe Harbor Statement
安全港聲明
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
本新聞稿中的一些陳述是前瞻性陳述。這些前瞻性陳述是基於我們目前對未來事件的預期和預測，大體上與我們對業務發展的計劃、目標和期望有關。儘管管理層認為這些前瞻性陳述中反映或暗示的計劃和目標是合理的，但所有前瞻性陳述都包含風險和不確定因素，未來的實際結果可能與本新聞稿中表達的計劃、目標和預期大不相同。
For more information contact:
如需更多信息，請聯繫：
View original content to download multimedia:http://www.prnewswire.com/news-releases/triple-gene-announces-presentation-at-upcoming-biotech-showcase-investor-conference-300984120.html
查看原創內容以下載multimedia:http://www.prnewswire.com/news-releases/triple-gene-announces-presentation-at-upcoming-biotech-showcase-investor-conference-300984120.html
SOURCE Triple-Gene LLC
源三基因有限責任公司
譯文內容由第三人軟體翻譯。